Infliximab and Tofacitinib Attenuate Neutralizing Antibody Responses Against SARS-CoV-2 Ancestral and Omicron Variants in Inflammatory Bowel Disease Patients After 3 Doses of COVID-19 Vaccine

作者：Zhigang Liu, James L. Alexander, Kathy Weitung Lin, Kaixing Le, Xin Zhou, Hajir Ibraheim, Sulak Anandabaskaran, Aamir Saifuddin, Leon R. McFarlane, Nikhil Anand, Laura Constable, Rocío Seoane, Andrea D’Mello, Sharmili Balarajah, Lucy Hicks, Horace R. Williams, Jonathan W. Lo, Ailsa Hart, Daniel M. Altmann, Rosemary J. Boyton, Julian Teare, Rachel Nice, Claire Bewshea, James Goodhand, Nicholas A. Kennedy, Anna Barnes, John M. Kirkwood, Marian Parkinson, Helen Gardner‐Thorpe, Charlie W. Lees, Gareth Jones, Kate Covil, Lauranne Derikx, Francesca Fiorentino, Peter M. Irving, Miles Parkes, Rachel Linger, Klaartje Kok, Irish Lee, Bessie Cipriano, Kamal Patel, Shaji Sebastian, Alexandra Kent, Ijeoma Chukwurah, Sulaimaan Haq, Parita Shah, Stephanie Wilken-Smith, Anitha Ramanathan, Mikin Patel, Lidia Romanczuk, Rebecca King, Jason Domingo, Bridget Knight, Djamila Shamtally, Vivien Mendoza, Joanne Sanchez, Hannah Stark, Louise Bee, Charmaine Estember, Darcy Watkins, Sam Stone, Beatriz Gros Alcalde, Giuseppe Ruocco, Manisha Baden, Graham Cooke, Evgenia Kourampa, Ciro Pasquale, Elena Robisco-Diaz, Suhaylah Bhatti, Tariq Ahmad, Katrina M. Pollock, Nick Powell · 发表于：Gastroenterology · 年份：2022 · DOI：10.1053/j.gastro.2022.10.010 · 被引用次数：14 · 研究领域：SARS-CoV-2 and COVID-19 Research、COVID-19 Clinical Research Studies、Peripheral Neuropathies and Disorders

Vaccination is an effective population strategy for preventing severe COVID-19 disease and reducing infection transmission.1 The emergence of new variants, particularly more transmissible strains, such as the omicron variants, has resulted in high infection rates in unvaccinated and vaccinated individuals.2 Concerns about more transmissible variants are especially pertinent for immunosuppressed individuals, in whom vaccines are less immunogenic and less effective.3 We and others have shown that patients with inflammatory bowel disease (IBD) established on immunosuppressive drugs, including infliximab (an anti–tumor necrosis factor [TNF] monoclonal antibody) or tofacitinib (a pan–Janus kinase [JAK]-inhibitor), have reduced vaccine-induced humoral responses after 2 and 3 doses of COVID-19 vaccination.